A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

This study tests NT-175, a new type of immune cell therapy called a T-cell receptor therapy, in people with advanced solid tumors that carry two specific biological markers: a TP53 R175H gene mutation and a specific immune-related marker called HLA-A*02:01. The therapy uses the patient's own immune cells, engineered to recognize and attack cancer cells with this mutation. **You may be eligible if...** - You are 18 or older with advanced (stage III or IV) solid cancer including lung, colorectal, head/neck, pancreatic, breast, ovarian, or other cancers - Your tumor has been tested and has both the TP53 R175H mutation AND the HLA-A*02:01 marker - You have received at least one prior standard treatment with no available curative options - Your general health is good (ECOG 0–1) **You may NOT be eligible if...** - You have had a prior cell or gene therapy, stem cell transplant, or organ transplant - You had a stroke or heart attack within the past year - You have significant heart disease - You have Li-Fraumeni syndrome or a family history of it - You are pregnant or breastfeeding - You have an active immune disease requiring steroids Talk to your doctor to see if this trial is right for you.